Skip to Main Navigation
Skip to Page Content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/17759

TDMS Study 93021-06 Pathology Tables

NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01
Route: SKIN APPLICATION                                                                                           Time: 09:20:54

                                                         Final #1/Mice




       Facility:  BIORELIANCE

       Chemical CAS #:  538-75-0

       Lock Date:  02/24/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially In Study                          15           15           15           15           15           15           
  Early Deaths                                                                                                                      
    Moribund Sacrifice                                                                        2                         7           
    Natural Death                                                                             1            1            1           
  Survivors                                                                                                                         
    Terminal Sacrifice                                15           15           15           12           14            7           
                                                                                                                                    
  Animals Examined Microscopically                    15           15           15           15           15           15           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Liver                                              (15)         (15)         (15)         (15)         (14)         (15)         
      Hematopoietic Cell Proliferation                                                                                  1 (7%)      
      Hematopoietic Cell Proliferation, Focal                                                                           1 (7%)      
      Infiltration Cellular, Focal, Lymphocyte                      1 (7%)                    4 (27%)      1 (7%)       2 (13%)     
      Inflammation, Chronic Active, Focal                                                                               1 (7%)      
      Hepatocyte, Necrosis, Focal                      4 (27%)      6 (40%)      5 (33%)      4 (27%)      2 (14%)      1 (7%)      
      Periportal, Vacuolization Cytoplasmic, Focal                                            1 (7%)                                
   Stomach, Glandular                                 (15)         (15)         (15)         (15)         (14)         (14)         
      Infiltration Cellular, Focal, Lymphocyte                                                1 (7%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (15)         (15)         (15)         (15)         (14)         (13)         
      Subcapsular, Hyperplasia                                                                                          1 (8%)      
      Subcapsular, Hyperplasia, Focal                 13 (87%)     13 (87%)     12 (80%)     13 (87%)     14 (100%)     9 (69%)     
   Thyroid Gland                                      (13)         (15)         (15)         (14)         (13)         (13)         
      Ectopic Thymus                                                2 (13%)      3 (20%)      1 (7%)       1 (8%)                   
      Inflammation, Chronic Active, Focal              1 (8%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    2                                                              
                                                                                                                                   
NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Ovary                                              (15)         (15)         (15)         (15)         (14)         (14)         
      Atrophy                                                                    1 (7%)                                 1 (7%)      
   Uterus                                             (15)         (15)         (15)         (15)         (14)         (14)         
      Endometrium, Hyperplasia, Cystic                14 (93%)     15 (100%)    15 (100%)    13 (87%)     13 (93%)      7 (50%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (15)         (15)         (15)         (15)         (14)         (15)         
      Myeloid Cell, Hyperplasia                                                               3 (20%)      1 (7%)       8 (53%)     
   Lymph Node                                                                                (1)                                    
      Inguinal, Hyperplasia, Lymphoid                                                         1 (100%)                              
   Lymph Node, Mandibular                             (15)         (15)         (14)         (14)         (14)         (14)         
      Hyperplasia, Lymphoid                            1 (7%)                                 2 (14%)      3 (21%)                  
   Lymph Node, Mediastinal                            (14)         (15)         (15)         (12)         (13)         (13)         
      Hyperplasia, Lymphoid                                                      1 (7%)                                             
   Spleen                                             (15)         (15)         (15)         (15)         (14)         (14)         
      Hematopoietic Cell Proliferation                15 (100%)    15 (100%)    15 (100%)    15 (100%)    13 (93%)     13 (93%)     
      Pigmentation                                                                                                      1 (7%)      
   Thymus                                             (15)         (15)         (15)         (15)         (14)         (13)         
      Atrophy, Diffuse                                                                                                  2 (15%)     
      Atrophy, Focal                                                2 (13%)      1 (7%)                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (15)         (15)         (15)         (15)         (14)         (14)         
      Inflammation, Chronic Active, Focal                                                                               1 (7%)      
   Skin                                               (15)         (15)         (15)         (15)         (15)         (15)         
      Control, Ulcer, Focal                                                                   1 (7%)                    2 (13%)     
      Dermis, Epidermis, Hyperplasia, Focal                                                                             1 (7%)      
      Dermis, Control, Inflammation, Chronic                                                                                        
          Active, Focal                                                                       3 (20%)      1 (7%)       2 (13%)     
      Dermis, Skin, Site of Application, Fibrosis                                                                       1 (7%)      
      Dermis, Skin, Site of Application,                                                                                            
          Inflammation, Chronic Active, Focal          1 (7%)                                13 (87%)      2 (13%)      9 (60%)     
      Epidermis, Control, Hyperplasia, Focal                                                  2 (13%)                   1 (7%)      
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia, Diffuse                                                   1 (7%)       2 (13%)                               
      Epidermis, Skin, Site of Application,                                                                                         
          Hyperplasia, Focal                                        1 (7%)       5 (33%)     11 (73%)      1 (7%)       8 (53%)     
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    3                                                              
                                                                                                                                   
NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
INTEGUMENTARY SYSTEM - CONT                                                                                                         
      Sebaceous Gland, Control, Hyperplasia, Focal                                            1 (7%)                    1 (7%)      
      Sebaceous Gland, Skin, Site of Application,                                                                                   
           Hyperplasia, Focal                                                                 3 (20%)                   3 (20%)     
      Skin, Site of Application, Hyperkeratosis,                                                                                    
           Diffuse                                                                            1 (7%)       1 (7%)                   
      Skin, Site of Application, Parakeratosis,                                                                                     
           Focal                                                                              1 (7%)       1 (7%)                   
      Skin, Site of Application, Ulcer, Focal                                                 2 (13%)      1 (7%)       8 (53%)     
      Subcutaneous Tissue, Control, Inflammation,                                                                                   
           Chronic Active, Focal                                                              1 (7%)                    2 (13%)     
      Subcutaneous Tissue, Skin, Site of                                                                                            
          Application, Inflammation, Chronic, Focal                                                        1 (7%)                   
      Subcutaneous Tissue, Skin, Site of                                                                                            
          Application, Inflammation, Chronic                                                                                        
          Active, Focal                                                                       2 (13%)                   8 (53%)     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (15)         (15)         (15)         (15)         (14)         (15)         
      Alveolar Epithelium, Hyperplasia, Focal                                    1 (7%)                                             
      Alveolar Epithelium, Inflammation, Chronic                                                                                    
          Active, Focal                                             1 (7%)                                                          
      Alveolus, Inflammation, Chronic Active, Focal    1 (7%)                                              1 (7%)       1 (7%)      
      Perivascular, Infiltration Cellular, Focal,                                                                                   
           Lymphocyte                                  1 (7%)                                              2 (14%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                             Page    4                                                              
                                                                                                                                   
NTP Experiment-Test: 93021-06         INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a)               Report: PEIRPT03  
Study Type: SUBCHRON 26-WEEK                          DICYCLOHEXYLCARBODIIMIDE (DCC)                              Date: 01/10/01    
Route: SKIN APPLICATION                                                                                           Time: 09:20:54    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         MICE:P53+/-(C57BL/6) FEMALE               VEHICLE      0.75         1.5          3.0          6.0          12.0            
                                                                MG/KG        MG/KG        MG/KG        MG/KG        MG/KG           
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (15)         (15)         (15)         (15)         (14)         (14)         
      Infiltration Cellular, Focal, Lymphocyte                      1 (7%)                                                          
      Pelvis, Infiltration Cellular, Focal,                                                                                         
          Lymphocyte                                                                          1 (7%)                                
                                                                                                                                    
                                                                                                                                    
a  Number of animals examined microscopically at site and number of animals with lesion                                             
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page    5                                                              
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------